RLM - Realm Therapeutics Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7500
-0.2700 (-8.94%)
At close: 12:05PM EDT
Stock chart is not supported by your current browser
Previous Close3.0200
Open3.0100
Bid3.0400 x 4000
Ask3.4500 x 2200
Day's Range2.7500 - 3.0000
52 Week Range1.3500 - 13.0000
Volume285,355
Avg. Volume30,893
Market Cap12.822M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.9230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    ESSA Pharma, Realm Therapeutics To Merge In $20M Deal

    The acquisition is expected to be completed by mid 2019. Once the acquisition is complete the company will continue to operate as ESSA Pharma, and trade on the Nasdaq and TSX-V Market and operating in the United States as ESSA Pharmaceuticals Corp. The terms of the acquisition value Realm's issued and outstanding shares at approximately $21.5 million, which represents a 5 percent premium over Realm's estimated net cash amount of $20.5 million at the closing of the acquisition.

  • CNW Group3 days ago

    Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

    Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

  • PR Newswirelast month

    Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing

    MALVERN, Pa. , April 10, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM) today announces that its 2018 Annual Report is now available on the Company's website, www.realmtx.com , and will be posted ...

  • PR Newswirelast month

    Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing

    MALVERN, Pa., April 5, 2019 /PRNewswire/ -- Realm Therapeutics plc (RLM) (the "Company") today announced that the Company received written notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the Company's recent Assets Disposal, the Staff believes the Company is a "shell company" (i.e., a non-operating entity) and, as such, the continued listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares on Nasdaq is no longer warranted. The Staff cited Nasdaq Listing Rule 5101 as the basis for its determination.

  • PR Newswire2 months ago

    Realm Therapeutics Announces Completion of Assets Disposal

    MALVERN, Pa., March 29, 2019 /PRNewswire/ --   Realm Therapeutics plc (NASDAQ: RLM) today announces the completion of its previously announced Assets Disposal representing certain assets, which comprise ...

  • Malvern biopharm firm to shed assets in $10M deal
    American City Business Journals2 months ago

    Malvern biopharm firm to shed assets in $10M deal

    The company began exploring 'strategic options' after a key product failed in midstage clinical testing in September.

  • PR Newswire2 months ago

    Realm Therapeutics Announces Cancellation of AIM Listing

    MALVERN, Pa. , March 26, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, ...

  • PR Newswire2 months ago

    Realm Therapeutics Announces Result of General Meeting

    All Resolutions Passed Reminder: Process to Convert Ordinary Shares into ADSs MALVERN, Pa. , March 15, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company ...

  • PR Newswire3 months ago

    Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting

    MALVERN, Pa., Feb. 15, 2019 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, today provides an update on its previously announced strategic review. In line with the announcement of November 29, 2018, the Company has now agreed to sell certain Assets, which comprise the  Vashe® wound care royalty stream, an FDA 510(k)-cleared anti-itch hydrogel, which was formerly marketed as Aurstat™, HOCI related equipment, intellectual property (including know-how, patents and copyrights), program records, and certain assigned contracts and intellectual property licenses. The Company's primary assets also include its cash, cash equivalents, and short-term investments.

  • Our Take On Realm Therapeutics Plc’s (LON:RLM) CEO Salary
    Simply Wall St.5 months ago

    Our Take On Realm Therapeutics Plc’s (LON:RLM) CEO Salary

    Alex Martin became the CEO of Realm Therapeutics Plc (LON:RLM) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...

  • ACCESSWIRE6 months ago

    Healthcare Stocks Continue To Rally Amid Volatile Market Conditions; Premier Health Group, Inc. (PHGRF) (PHGI), Inovalon Holdings, Community Health Systems, Realm Therapeutics

    CORAL GABLES, FL / ACCESSWIRE / November 29, 2018 / Healthcarestocks remain in focus this week after the stock market posted its worst Black Friday session last week followed by a 1000 point move during the first half of this week. Heading into the last few days of the month, 4 healthcare stocks to watch include: PremierHealth Group, Inc. (PHGRF) (PHGI), Inovalon Holdings, Inc. (INOV), Community Health Systems, Inc. (CYH), and Realm Therapeutics Plc (RLM). PremierHealth Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.

  • PR Newswire6 months ago

    Realm Therapeutics Provides Update on Strategic Review

    MALVERN, Pa., Nov. 29, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides an update on timing of the ongoing formal sale process as part of the previously announced strategic review. On September 17, 2018, Realm announced the commencement of a strategic review, including the evaluation of a potential sale of the Company being conducted within the context of a formal sale process (as referred to in the City Code on Takeovers and Mergers (the "Code")). As part of the strategic review, Realm received multiple indications of interest which include a potential sale of the Company, contemplated as a reverse merger, directly and through parties contacted by MTS Partners, LP acting as an advisor in the strategic review.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and Realm Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / Viking Therapeutics and Realm Therapeutics were big winners in the biotech arena on Tuesday with both shares seeing big gains. Viking shares blasted north ...

  • PR Newswire8 months ago

    Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process

    MALVERN, Pa., Sept. 17, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration hypochlorous acid (HOCl), today provides a corporate update following the August 14, 2018 announcement of top-line results of the Company's Phase 2 trial of PR022 in Atopic Dermatitis and announces the hiring of MTS Health Partners, L.P. to act as an advisor in relation to a strategic review that has been initiated by the Company, which may include the potential sale of the Company as a possible outcome. "A full analysis of our Atopic Dermatitis study results showed a statistically significant efficacy signal in a sub-population treated with the higher dose formulation.

  • PR Newswire9 months ago

    Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results

    Company Hosting Conference Call Today at 9:00 AM ET / 2:00 PM BST MALVERN, Pa. , Aug. 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company ...

  • PR Newswire9 months ago

    Realm Therapeutics to Report First Half 2018 Financial Results

    MALVERN, Pa. , Aug. 7, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, ...

  • PR Newswire10 months ago

    Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis

    MALVERN, Pa., July 10, 2018  /PRNewswire/ -- Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces the publication of a pre-clinical study demonstrating comparable activity between PR022, Realm's proprietary topical gel formulation of high concentration hypochlorous acid (HOCl), and tofacitinib, a topical Janus kinase (JAK) inhibitor, in the treatment of Atopic Dermatitis. The article, "Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model" was published in the current issue of BMC Pharmacology and Toxicology.

  • PR Newswire10 months ago

    Realm Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs

    Nasdaq: RLM) (the "Company"), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today separately announced that in connection with a listing of American Depositary Shares ("ADSs") representing ordinary shares of nominal value of 10 pence in the capital of the Company ("Ordinary Shares") on the Nasdaq Capital Market ("Nasdaq"), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs are expected to be listed for trading on such market under the symbol "RLM" on July 5, 2018.

  • PR Newswire10 months ago

    Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares

    Nasdaq: RLM) (the "Company") a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that in connection with a listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares on the Nasdaq Capital Market ("Nasdaq"), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs are expected to be listed for trading on such market under the symbol "RLM" on July 5, 2018.